Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) EBIT Margin (2018 - 2025)

Serina Therapeutics' EBIT Margin history spans 8 years, with the latest figure at 4280.77% for Q2 2025.

  • For Q2 2025, EBIT Margin rose 329962.0% year-over-year to 4280.77%; the TTM value through Sep 2025 reached 20141.38%, down 1988075.0%, while the annual FY2024 figure was 30442.86%, 3034362.0% down from the prior year.
  • EBIT Margin for Q2 2025 was 4280.77% at Serina Therapeutics, down from 39635.71% in the prior quarter.
  • Across five years, EBIT Margin topped out at 39635.71% in Q4 2024 and bottomed at 46420.0% in Q1 2024.
  • The 5-year median for EBIT Margin is 6975.0% (2021), against an average of 11516.71%.
  • The largest YoY upside for EBIT Margin was 3952975bps in 2024 against a maximum downside of -4321333bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 6914.81% in 2021, then plummeted by -222bps to 22275.0% in 2022, then surged by 100bps to 105.96% in 2023, then soared by 37306bps to 39635.71% in 2024, then tumbled by -111bps to 4280.77% in 2025.
  • Per Business Quant, the three most recent readings for SER's EBIT Margin are 4280.77% (Q2 2025), 39635.71% (Q4 2024), and 37942.86% (Q3 2024).